FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ALX4-STK33

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ALX4-STK33
FusionPDB ID: 4130
FusionGDB2.0 ID: 4130
HgeneTgene
Gene symbol

ALX4

STK33

Gene ID

60529

65975

Gene nameALX homeobox 4serine/threonine kinase 33
SynonymsCRS5|FND2-
Cytomap

11p11.2

11p15.4

Type of geneprotein-codingprotein-coding
Descriptionhomeobox protein aristaless-like 4aristaless-like homeobox 4homeodomain transcription factor ALX4serine/threonine-protein kinase 33
Modification date2020031320200320
UniProtAcc

Q9H161

Main function of 5'-partner protein: FUNCTION: Transcription factor involved in skull and limb development. Plays an essential role in craniofacial development, skin and hair follicle development. {ECO:0000269|PubMed:19692347}.
.
Ensembl transtripts involved in fusion geneENST idsENST00000329255, ENST00000447869, 
ENST00000473980, ENST00000358872, 
ENST00000534493, ENST00000315204, 
ENST00000396672, ENST00000396673, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score3 X 3 X 3=273 X 4 X 2=24
# samples 34
** MAII scorelog2(3/27*10)=0.15200309344505
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
log2(4/24*10)=0.736965594166206
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
Fusion gene context

PubMed: ALX4 [Title/Abstract] AND STK33 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ALX4 [Title/Abstract] AND STK33 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ALX4(44289044)-STK33(8414257), # samples:3
Anticipated loss of major functional domain due to fusion event.ALX4-STK33 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ALX4-STK33 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ALX4-STK33 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ALX4-STK33 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ALX4-STK33 seems lost the major protein functional domain in Hgene partner, which is a transcription factor due to the frame-shifted ORF.
ALX4-STK33 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
ALX4-STK33 seems lost the major protein functional domain in Tgene partner, which is a kinase due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr11:44289044/chr11:8414257)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ALX4 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across STK33 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000329255ALX4chr1144289044-ENST00000396673STK33chr118414257-18501010891210373
ENST00000329255ALX4chr1144289044-ENST00000396672STK33chr118414257-18501010891210373
ENST00000329255ALX4chr1144289044-ENST00000315204STK33chr118414257-18501010891210373

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000329255ENST00000396673ALX4chr1144289044-STK33chr118414257-0.0125443890.9874556
ENST00000329255ENST00000396672ALX4chr1144289044-STK33chr118414257-0.0125443890.9874556
ENST00000329255ENST00000315204ALX4chr1144289044-STK33chr118414257-0.0125443890.9874556

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ALX4-STK33

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ALX4chr1144289044STK33chr1184142571010304TAYELPLLTRAENYAQSTAYEKQFPA

Top

Potential FusionNeoAntigen Information of ALX4-STK33 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ALX4-STK33_44289044_8414257.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ALX4-STK33chr1144289044chr1184142571010HLA-B45:01AENYAQSTA0.99790.96981019
ALX4-STK33chr1144289044chr1184142571010HLA-B50:02AENYAQSTA0.99550.70011019
ALX4-STK33chr1144289044chr1184142571010HLA-B15:02ENYAQSTAY0.8780.90881120
ALX4-STK33chr1144289044chr1184142571010HLA-B41:01AENYAQSTA0.44660.89091019
ALX4-STK33chr1144289044chr1184142571010HLA-B18:01ENYAQSTAY0.43350.7951120
ALX4-STK33chr1144289044chr1184142571010HLA-B15:18ENYAQSTAY0.34030.58471120
ALX4-STK33chr1144289044chr1184142571010HLA-B50:01AENYAQSTA0.30430.77551019
ALX4-STK33chr1144289044chr1184142571010HLA-B44:03AENYAQSTAY0.9990.96681020
ALX4-STK33chr1144289044chr1184142571010HLA-B35:01LPLLTRAENY0.99730.9509414
ALX4-STK33chr1144289044chr1184142571010HLA-B35:05LPLLTRAENY0.98230.8217414
ALX4-STK33chr1144289044chr1184142571010HLA-B18:01AENYAQSTAY0.8960.79411020
ALX4-STK33chr1144289044chr1184142571010HLA-B15:03AENYAQSTAY0.76690.64761020
ALX4-STK33chr1144289044chr1184142571010HLA-B45:01RAENYAQSTA0.73540.9468919
ALX4-STK33chr1144289044chr1184142571010HLA-B50:01RAENYAQSTA0.6920.8268919
ALX4-STK33chr1144289044chr1184142571010HLA-B50:02AENYAQSTAY0.68670.59251020
ALX4-STK33chr1144289044chr1184142571010HLA-B50:02RAENYAQSTA0.67370.7349919
ALX4-STK33chr1144289044chr1184142571010HLA-B41:01RAENYAQSTA0.65330.8566919
ALX4-STK33chr1144289044chr1184142571010HLA-B15:01RAENYAQSTAY0.99640.8196920
ALX4-STK33chr1144289044chr1184142571010HLA-B39:06TRAENYAQSTA0.99460.9014819
ALX4-STK33chr1144289044chr1184142571010HLA-B15:25RAENYAQSTAY0.99390.8856920
ALX4-STK33chr1144289044chr1184142571010HLA-B15:17RAENYAQSTAY0.97540.8665920
ALX4-STK33chr1144289044chr1184142571010HLA-B40:06AENYAQSTA0.99750.61971019
ALX4-STK33chr1144289044chr1184142571010HLA-B15:31ENYAQSTAY0.89170.7871120
ALX4-STK33chr1144289044chr1184142571010HLA-B15:21ENYAQSTAY0.87430.83911120
ALX4-STK33chr1144289044chr1184142571010HLA-B73:01TRAENYAQS0.68920.6318817
ALX4-STK33chr1144289044chr1184142571010HLA-B15:05AENYAQSTAY0.85520.7481020
ALX4-STK33chr1144289044chr1184142571010HLA-B40:06RAENYAQSTA0.8320.8742919
ALX4-STK33chr1144289044chr1184142571010HLA-B73:01TRAENYAQSTA0.99170.8943819
ALX4-STK33chr1144289044chr1184142571010HLA-B15:07RAENYAQSTAY0.99150.7063920
ALX4-STK33chr1144289044chr1184142571010HLA-B15:05RAENYAQSTAY0.97790.8424920
ALX4-STK33chr1144289044chr1184142571010HLA-C14:02NYAQSTAY0.53550.93271220
ALX4-STK33chr1144289044chr1184142571010HLA-C14:03NYAQSTAY0.53550.93271220
ALX4-STK33chr1144289044chr1184142571010HLA-B40:04AENYAQSTA0.97660.75251019
ALX4-STK33chr1144289044chr1184142571010HLA-B35:23ENYAQSTAY0.89690.7791120
ALX4-STK33chr1144289044chr1184142571010HLA-B35:20ENYAQSTAY0.89390.90251120
ALX4-STK33chr1144289044chr1184142571010HLA-B35:11ENYAQSTAY0.88840.82621120
ALX4-STK33chr1144289044chr1184142571010HLA-B15:11ENYAQSTAY0.88750.70871120
ALX4-STK33chr1144289044chr1184142571010HLA-B15:08ENYAQSTAY0.88350.70961120
ALX4-STK33chr1144289044chr1184142571010HLA-B35:24ENYAQSTAY0.86930.82171120
ALX4-STK33chr1144289044chr1184142571010HLA-B35:43ENYAQSTAY0.85170.71561120
ALX4-STK33chr1144289044chr1184142571010HLA-B18:04ENYAQSTAY0.81070.81041120
ALX4-STK33chr1144289044chr1184142571010HLA-B18:11ENYAQSTAY0.66370.73691120
ALX4-STK33chr1144289044chr1184142571010HLA-A25:01ENYAQSTAY0.6510.87831120
ALX4-STK33chr1144289044chr1184142571010HLA-B41:03AENYAQSTA0.54660.61351019
ALX4-STK33chr1144289044chr1184142571010HLA-B18:07ENYAQSTAY0.50640.74331120
ALX4-STK33chr1144289044chr1184142571010HLA-B18:08ENYAQSTAY0.47710.74241120
ALX4-STK33chr1144289044chr1184142571010HLA-B18:03ENYAQSTAY0.46470.78361120
ALX4-STK33chr1144289044chr1184142571010HLA-B18:05ENYAQSTAY0.43350.7951120
ALX4-STK33chr1144289044chr1184142571010HLA-B18:06ENYAQSTAY0.38950.8031120
ALX4-STK33chr1144289044chr1184142571010HLA-B50:04AENYAQSTA0.30430.77551019
ALX4-STK33chr1144289044chr1184142571010HLA-B50:05AENYAQSTA0.30430.77551019
ALX4-STK33chr1144289044chr1184142571010HLA-B44:26AENYAQSTAY0.9990.96681020
ALX4-STK33chr1144289044chr1184142571010HLA-B44:07AENYAQSTAY0.9990.96681020
ALX4-STK33chr1144289044chr1184142571010HLA-B44:13AENYAQSTAY0.9990.96681020
ALX4-STK33chr1144289044chr1184142571010HLA-B35:77LPLLTRAENY0.99730.9509414
ALX4-STK33chr1144289044chr1184142571010HLA-B35:24LPLLTRAENY0.99390.9476414
ALX4-STK33chr1144289044chr1184142571010HLA-B35:30LPLLTRAENY0.99230.921414
ALX4-STK33chr1144289044chr1184142571010HLA-B35:17LPLLTRAENY0.99230.921414
ALX4-STK33chr1144289044chr1184142571010HLA-B35:11LPLLTRAENY0.97950.9725414
ALX4-STK33chr1144289044chr1184142571010HLA-B15:53AENYAQSTAY0.94280.73241020
ALX4-STK33chr1144289044chr1184142571010HLA-B15:50AENYAQSTAY0.940.81731020
ALX4-STK33chr1144289044chr1184142571010HLA-B18:04AENYAQSTAY0.92930.80961020
ALX4-STK33chr1144289044chr1184142571010HLA-B18:11AENYAQSTAY0.92730.74291020
ALX4-STK33chr1144289044chr1184142571010HLA-B18:08AENYAQSTAY0.90870.73331020
ALX4-STK33chr1144289044chr1184142571010HLA-B15:54AENYAQSTAY0.90410.70111020
ALX4-STK33chr1144289044chr1184142571010HLA-B15:11LPLLTRAENY0.89630.9607414
ALX4-STK33chr1144289044chr1184142571010HLA-B18:05AENYAQSTAY0.8960.79411020
ALX4-STK33chr1144289044chr1184142571010HLA-B15:12AENYAQSTAY0.89470.8021020
ALX4-STK33chr1144289044chr1184142571010HLA-B18:03AENYAQSTAY0.87560.78131020
ALX4-STK33chr1144289044chr1184142571010HLA-B15:20AENYAQSTAY0.85410.82611020
ALX4-STK33chr1144289044chr1184142571010HLA-B18:06AENYAQSTAY0.85380.80241020
ALX4-STK33chr1144289044chr1184142571010HLA-B35:28AENYAQSTAY0.82230.86431020
ALX4-STK33chr1144289044chr1184142571010HLA-B35:20AENYAQSTAY0.80330.88361020
ALX4-STK33chr1144289044chr1184142571010HLA-B50:05RAENYAQSTA0.6920.8268919
ALX4-STK33chr1144289044chr1184142571010HLA-B50:04RAENYAQSTA0.6920.8268919
ALX4-STK33chr1144289044chr1184142571010HLA-B48:02AENYAQSTAY0.64070.84051020
ALX4-STK33chr1144289044chr1184142571010HLA-B15:34RAENYAQSTAY0.99640.8196920
ALX4-STK33chr1144289044chr1184142571010HLA-B15:33RAENYAQSTAY0.99640.8196920
ALX4-STK33chr1144289044chr1184142571010HLA-B15:125RAENYAQSTAY0.99640.8196920
ALX4-STK33chr1144289044chr1184142571010HLA-B15:27RAENYAQSTAY0.9960.8009920
ALX4-STK33chr1144289044chr1184142571010HLA-B15:135RAENYAQSTAY0.99560.8189920
ALX4-STK33chr1144289044chr1184142571010HLA-B15:39RAENYAQSTAY0.99390.7871920
ALX4-STK33chr1144289044chr1184142571010HLA-B15:50RAENYAQSTAY0.99070.8625920
ALX4-STK33chr1144289044chr1184142571010HLA-B15:35RAENYAQSTAY0.98970.8144920
ALX4-STK33chr1144289044chr1184142571010HLA-B15:20RAENYAQSTAY0.97860.8957920
ALX4-STK33chr1144289044chr1184142571010HLA-B35:28RAENYAQSTAY0.97010.915920

Top

Potential FusionNeoAntigen Information of ALX4-STK33 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ALX4-STK33_44289044_8414257.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ALX4-STK33chr1144289044chr1184142571010DRB1-0901AENYAQSTAYEKQFP1025
ALX4-STK33chr1144289044chr1184142571010DRB1-0902AENYAQSTAYEKQFP1025
ALX4-STK33chr1144289044chr1184142571010DRB1-0902RAENYAQSTAYEKQF924
ALX4-STK33chr1144289044chr1184142571010DRB1-0902TRAENYAQSTAYEKQ823
ALX4-STK33chr1144289044chr1184142571010DRB1-0902ENYAQSTAYEKQFPA1126
ALX4-STK33chr1144289044chr1184142571010DRB1-0903AENYAQSTAYEKQFP1025
ALX4-STK33chr1144289044chr1184142571010DRB1-0903RAENYAQSTAYEKQF924
ALX4-STK33chr1144289044chr1184142571010DRB1-0903TRAENYAQSTAYEKQ823
ALX4-STK33chr1144289044chr1184142571010DRB1-0904AENYAQSTAYEKQFP1025
ALX4-STK33chr1144289044chr1184142571010DRB1-0905AENYAQSTAYEKQFP1025
ALX4-STK33chr1144289044chr1184142571010DRB1-0907AENYAQSTAYEKQFP1025
ALX4-STK33chr1144289044chr1184142571010DRB1-0907RAENYAQSTAYEKQF924
ALX4-STK33chr1144289044chr1184142571010DRB1-0907TRAENYAQSTAYEKQ823
ALX4-STK33chr1144289044chr1184142571010DRB1-0908AENYAQSTAYEKQFP1025
ALX4-STK33chr1144289044chr1184142571010DRB1-0908RAENYAQSTAYEKQF924
ALX4-STK33chr1144289044chr1184142571010DRB1-0908TRAENYAQSTAYEKQ823
ALX4-STK33chr1144289044chr1184142571010DRB1-0909AENYAQSTAYEKQFP1025
ALX4-STK33chr1144289044chr1184142571010DRB5-0101AENYAQSTAYEKQFP1025
ALX4-STK33chr1144289044chr1184142571010DRB5-0101RAENYAQSTAYEKQF924
ALX4-STK33chr1144289044chr1184142571010DRB5-0101TRAENYAQSTAYEKQ823
ALX4-STK33chr1144289044chr1184142571010DRB5-0101ENYAQSTAYEKQFPA1126
ALX4-STK33chr1144289044chr1184142571010DRB5-0102AENYAQSTAYEKQFP1025
ALX4-STK33chr1144289044chr1184142571010DRB5-0102RAENYAQSTAYEKQF924
ALX4-STK33chr1144289044chr1184142571010DRB5-0103AENYAQSTAYEKQFP1025
ALX4-STK33chr1144289044chr1184142571010DRB5-0103RAENYAQSTAYEKQF924
ALX4-STK33chr1144289044chr1184142571010DRB5-0104AENYAQSTAYEKQFP1025
ALX4-STK33chr1144289044chr1184142571010DRB5-0104RAENYAQSTAYEKQF924
ALX4-STK33chr1144289044chr1184142571010DRB5-0104TRAENYAQSTAYEKQ823
ALX4-STK33chr1144289044chr1184142571010DRB5-0104ENYAQSTAYEKQFPA1126
ALX4-STK33chr1144289044chr1184142571010DRB5-0105AENYAQSTAYEKQFP1025
ALX4-STK33chr1144289044chr1184142571010DRB5-0105RAENYAQSTAYEKQF924
ALX4-STK33chr1144289044chr1184142571010DRB5-0105TRAENYAQSTAYEKQ823
ALX4-STK33chr1144289044chr1184142571010DRB5-0105ENYAQSTAYEKQFPA1126
ALX4-STK33chr1144289044chr1184142571010DRB5-0108NAENYAQSTAYEKQFP1025
ALX4-STK33chr1144289044chr1184142571010DRB5-0108NRAENYAQSTAYEKQF924
ALX4-STK33chr1144289044chr1184142571010DRB5-0111AENYAQSTAYEKQFP1025
ALX4-STK33chr1144289044chr1184142571010DRB5-0111RAENYAQSTAYEKQF924
ALX4-STK33chr1144289044chr1184142571010DRB5-0111TRAENYAQSTAYEKQ823
ALX4-STK33chr1144289044chr1184142571010DRB5-0111ENYAQSTAYEKQFPA1126
ALX4-STK33chr1144289044chr1184142571010DRB5-0112AENYAQSTAYEKQFP1025
ALX4-STK33chr1144289044chr1184142571010DRB5-0112RAENYAQSTAYEKQF924
ALX4-STK33chr1144289044chr1184142571010DRB5-0112TRAENYAQSTAYEKQ823
ALX4-STK33chr1144289044chr1184142571010DRB5-0112ENYAQSTAYEKQFPA1126
ALX4-STK33chr1144289044chr1184142571010DRB5-0112LTRAENYAQSTAYEK722
ALX4-STK33chr1144289044chr1184142571010DRB5-0113AENYAQSTAYEKQFP1025
ALX4-STK33chr1144289044chr1184142571010DRB5-0113RAENYAQSTAYEKQF924
ALX4-STK33chr1144289044chr1184142571010DRB5-0113TRAENYAQSTAYEKQ823
ALX4-STK33chr1144289044chr1184142571010DRB5-0113ENYAQSTAYEKQFPA1126
ALX4-STK33chr1144289044chr1184142571010DRB5-0114AENYAQSTAYEKQFP1025
ALX4-STK33chr1144289044chr1184142571010DRB5-0114RAENYAQSTAYEKQF924
ALX4-STK33chr1144289044chr1184142571010DRB5-0114TRAENYAQSTAYEKQ823
ALX4-STK33chr1144289044chr1184142571010DRB5-0114ENYAQSTAYEKQFPA1126
ALX4-STK33chr1144289044chr1184142571010DRB5-0203AENYAQSTAYEKQFP1025

Top

Fusion breakpoint peptide structures of ALX4-STK33

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
5277LLTRAENYAQSTAYALX4STK33chr1144289044chr1184142571010

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ALX4-STK33

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN5277LLTRAENYAQSTAY-7.9962-8.1096
HLA-B14:023BVN5277LLTRAENYAQSTAY-5.70842-6.74372
HLA-B52:013W395277LLTRAENYAQSTAY-6.83737-6.95077
HLA-B52:013W395277LLTRAENYAQSTAY-4.4836-5.5189
HLA-A11:014UQ25277LLTRAENYAQSTAY-10.0067-10.1201
HLA-A11:014UQ25277LLTRAENYAQSTAY-9.03915-10.0745
HLA-A24:025HGA5277LLTRAENYAQSTAY-6.56204-6.67544
HLA-A24:025HGA5277LLTRAENYAQSTAY-5.42271-6.45801
HLA-B44:053DX85277LLTRAENYAQSTAY-7.85648-8.89178
HLA-B44:053DX85277LLTRAENYAQSTAY-5.3978-5.5112
HLA-A02:016TDR5277LLTRAENYAQSTAY-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of ALX4-STK33

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ALX4-STK33chr1144289044chr1184142571019AENYAQSTATACGCCCAGTCTACTGCTTATGAAAAG
ALX4-STK33chr1144289044chr1184142571020AENYAQSTAYTACGCCCAGTCTACTGCTTATGAAAAGCAA
ALX4-STK33chr1144289044chr1184142571120ENYAQSTAYGCCCAGTCTACTGCTTATGAAAAGCAA
ALX4-STK33chr1144289044chr1184142571220NYAQSTAYCAGTCTACTGCTTATGAAAAGCAA
ALX4-STK33chr1144289044chr118414257414LPLLTRAENYCTCACCCGAGCTGAGAACTACGCCCAGTCT
ALX4-STK33chr1144289044chr118414257817TRAENYAQSGAGAACTACGCCCAGTCTACTGCTTAT
ALX4-STK33chr1144289044chr118414257819TRAENYAQSTAGAGAACTACGCCCAGTCTACTGCTTATGAAAAG
ALX4-STK33chr1144289044chr118414257919RAENYAQSTAAACTACGCCCAGTCTACTGCTTATGAAAAG
ALX4-STK33chr1144289044chr118414257920RAENYAQSTAYAACTACGCCCAGTCTACTGCTTATGAAAAGCAA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
ALX4-STK33chr1144289044chr1184142571025AENYAQSTAYEKQFPTACGCCCAGTCTACTGCTTATGAAAAGCAATTTCCTGCAACCAGT
ALX4-STK33chr1144289044chr1184142571126ENYAQSTAYEKQFPAGCCCAGTCTACTGCTTATGAAAAGCAATTTCCTGCAACCAGTAAG
ALX4-STK33chr1144289044chr118414257722LTRAENYAQSTAYEKGCTGAGAACTACGCCCAGTCTACTGCTTATGAAAAGCAATTTCCT
ALX4-STK33chr1144289044chr118414257823TRAENYAQSTAYEKQGAGAACTACGCCCAGTCTACTGCTTATGAAAAGCAATTTCCTGCA
ALX4-STK33chr1144289044chr118414257924RAENYAQSTAYEKQFAACTACGCCCAGTCTACTGCTTATGAAAAGCAATTTCCTGCAACC

Top

Information of the samples that have these potential fusion neoantigens of ALX4-STK33

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BRCAALX4-STK33chr1144289044ENST00000329255chr118414257ENST00000315204TCGA-B6-A0X7-01A

Top

Potential target of CAR-T therapy development for ALX4-STK33

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to ALX4-STK33

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ALX4-STK33

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource